SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
Alibaba Shares Fall as AI Spending Hits Profit 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Add as a preferred source on Google
ROCKVILLE, MD, May 07, 2018 --
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will provide a corporate overview presentation at Deutsche Bank's 43rd Annual Health Care Conference in Boston on May 8, 2018 at 8:00 am (ET).
A webcast of the conference presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.
###
Contacts: Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, [email protected] Karen Sharma, Senior Vice President MacDougall Biomedical Communications 1-781-235-3060, [email protected]
